Phenotypes of Obesity Hypoventilation Syndrome: Characteristics and Outcomes

Juan F. Masa-Jiménez; Victor R. Ramírez-Molina; Celia De Dios-Calama

doi:10.1055/a-2591-5583

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2025; 46(02): 202-212
DOI: 10.1055/a-2591-5583

Review Article

Phenotypes of Obesity Hypoventilation Syndrome: Characteristics and Outcomes

Juan F. Masa-Jiménez

¹Emeritus Pulmonologist in San Pedro de Alcántara Hospital, Cáceres, Spain

²Academic Numerary of the Royal Academy of Medicine in Salamanca University, Salamanca, Spain

,

Victor R. Ramírez-Molina

³Department of Pulmonologist and Somnologist Attached to Hospital H+ Querétaro, Querétaro, México

,

Celia De Dios-Calama

⁴Department of Pulmonologist in the Pulmonary Service San Pedro de Alcántara Hospital, Cáceres, Spain

› Institutsangaben

Abstract

Obesity hypoventilation syndrome (OHS) is defined by the combination of obesity (body mass index [BMI] ≥30 kg/m²), sleep-disordered breathing, and daytime hypercapnia (arterial carbon dioxide tension [PaCO₂] ≥45 mm Hg at sea level) during wakefulness occurring in the absence of an alternative neuromuscular, mechanical, or metabolic explanation for hypoventilation. Patients with OHS can be classified by phenotypes depending on whether or not they have obstructive respiratory events: hypoventilation and no or not significant obstructive sleep apnea (OSA) and hypoventilation and significant OSA; we also add a third phenotype, which is the hospitalized patient with acute-on-chronic respiratory failure. We describe the mid- and long-term outcomes with and without positive airway pressure (PAP) by these three phenotypes.

Keywords

obesity hypoventilation syndrome - apnea - positive airway pressure - CPAP - non-invasive ventilation

Volltext

Referenzen

References
1 Mokhlesi B, Kryger MH, Grunstein RR. Assessment and management of patients with obesity hypoventilation syndrome. Proc Am Thorac Soc 2008; 5 (02) 218-225
2 Masa JF, Corral J, Alonso ML. et al; Spanish Sleep Network. Efficacy of different treatment alternatives for obesity hypoventilation syndrome. Pickwick study. Am J Respir Crit Care Med 2015; 192 (01) 86-95
3 Ramírez Molina VR, Masa Jiménez JF, Gómez de Terreros Caro FJ, Corral Peñafiel J. Effectiveness of different treatments in obesity hypoventilation syndrome. Pulmonology 2020; 26 (06) 370-377
4 Randerath W, Verbraecken J, Andreas S. et al. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep. Eur Respir J 2017; 49 (01) 1600959
5 Piper A, Pépin JL, Hart N. Positive airway pressure in obesity hypoventilation syndrome: is it worth it?. Thorax 2020; 75 (06) 439-440
6 Marik PE, Chen C. The clinical characteristics and hospital and post-hospital survival of patients with the obesity hypoventilation syndrome: analysis of a large cohort. Obes Sci Pract 2016; 2 (01) 40-47
7 Ramírez-Molina VR, Gómez-de-Terreros FJ, Barca-Durán J, Masa JF. Non-invasive positive airway pressure in obesity hypoventilation syndrome and chronic obstructive pulmonary disease: present and future perspectives. COPD 2017; 14 (04) 418-428
8 Masa JF, Benítez I, Sánchez-Quiroga MÁ. et al; Spanish Sleep Network. Long-term noninvasive ventilation in obesity hypoventilation syndrome without severe OSA: the Pickwick randomized controlled trial. Chest 2020; 158 (03) 1176-1186
9 Masa JF, Pépin J-L, Borel J-C, Mokhlesi B, Murphy PB, Sánchez-Quiroga MÁ. Obesity hypoventilation syndrome. Eur Respir Rev 2019; 28 (151) 180097
10 Antoine MH, Sankari A, Bollu PC. Obesity-Hypoventilation Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; January 2024
11 Piper AJ, Grunstein RR. Obesity hypoventilation syndrome: mechanisms and management. Am J Respir Crit Care Med 2011; 183 (03) 292-298
12 Mokhlesi B, Masa JF, Brozek JL. et al. Evaluation and management of obesity hypoventilation syndrome. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2019; 200 (03) e6-e24 Erratum in: Am J Respir Crit Care Med. 2019 Nov 15;200(10):1326
13 Berger KI, Ayappa I, Sorkin IB. et al. Postevent ventilation as a function of CO(2) load during respiratory events in obstructive sleep apnea. J Appl Physiol 1985; 2002; 93 (03) 917-924
14 Borel JC, Tamisier R, Gonzalez-Bermejo J. et al. Noninvasive ventilation in mild obesity hypoventilation syndrome: a randomized controlled trial. Chest 2012; 141 (03) 692-702
15 Mokhlesi B, Masa JF, Afshar M. et al. The effect of hospital discharge with empiric noninvasive ventilation on mortality in hospitalized patients with obesity hypoventilation syndrome. An individual patient data meta-analysis. Ann Am Thorac Soc 2020; 17 (05) 627-637
16 Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018; 27 (04) 740-756
17 Drucker DJ, Holst JJ. The expanding incretin universe: from basic biology to clinical translation. Diabetologia 2023; 66 (10) 1765-1779
18 Gasoyan H, Pfoh ER, Schulte R, Le P, Butsch WS, Rothberg MB. One-year weight reduction with semaglutide or liraglutide in clinical practice. JAMA Netw Open 2024; 7 (09) e2433326
19 Rodriguez PJ, Goodwin Cartwright BM, Gratzl S. et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med 2024; 184 (09) 1056-1064
20 Lincoff AM, Brown-Frandsen K, Colhoun HM. et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023; 389 (24) 2221-2232
21 Stefanou M-I, Palaiodimou L, Theodorou A. et al. Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis. Ther Adv Neurol Disord 2024; 17: 17 562864241281903
22 Malhotra A, Grunstein RR, Fietze I. et al; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 2024; 391 (13) 1193-1205 . Erratum in: N Engl J Med. 2024 Oct 17;391(15):1464
23 O'Donnell C, Crilly S, O'Mahony A. et al. Continuous positive airway pressure but not GLP1-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: a randomized proof-of-concept study. Ann Am Thorac Soc 2024; 21 (03) 464-473
24 Jiang W, Li W, Cheng J, Li W, Cheng F. Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea. Sleep Breath 2023; 27 (05) 1687-1694
25 Blackman A, Foster GD, Zammit G. et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) 2016; 40 (08) 1310-1319
26 Sullivan CE, Berthon-Jones M, Issa FG. Remission of severe obesity-hypoventilation syndrome after short-term treatment during sleep with nasal continuous positive airway pressure. Am Rev Respir Dis 1983; 128 (01) 177-181
27 Mokhlesi B, Tulaimat A. Recent advances in obesity hypoventilation syndrome. Chest 2007; 132 (04) 1322-1336
28 Borel JC, Burel B, Tamisier R. et al. Comorbidities and mortality in hypercapnic obese under domiciliary noninvasive ventilation. PLoS One 2013; 8 (01) e52006
29 Berg G, Delaive K, Manfreda J, Walld R, Kryger MH. The use of health-care resources in obesity-hypoventilation syndrome. Chest 2001; 120 (02) 377-383
30 Jennum P, Ibsen R, Kjellberg J. Morbidity prior to a diagnosis of sleep-disordered breathing: a controlled national study. J Clin Sleep Med 2013; 9 (02) 103-108
31 Masa JF, Corral J, Romero A. et al; Spanish Sleep Network(∗). Protective cardiovascular effect of sleep apnea severity in obesity hypoventilation syndrome. Chest 2016; 150 (01) 68-79
32 Bjork S, Jain D, Marliere MH, Predescu SA, Mokhlesi B. Obstructive sleep apnea, obesity hypoventilation syndrome, and pulmonary hypertension: a state-of-the-art review. Sleep Med Clin 2024; 19 (02) 307-325
33 Nowbar S, Burkart KM, Gonzales R. et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med 2004; 116 (01) 1-7
34 Budweiser S, Riedl SG, Jörres RA, Heinemann F, Pfeifer M. Mortality and prognostic factors in patients with obesity-hypoventilation syndrome undergoing noninvasive ventilation. J Intern Med 2007; 261 (04) 375-383
35 Zheng Y, Phillips CL, Sivam S. et al. Cardiovascular disease in obesity hypoventilation syndrome—a review of potential mechanisms and effects of therapy. Sleep Med Rev 2021; 60: 101530
36 Lavie L, Lavie P. Reduced cardiovascular morbidity in obesity-hypoventilation syndrome: an ischemic preconditioning protective effect?. Chest 2016; 150 (01) 5-6
37 Masa JF, Corral J, Caballero C. et al; Spanish Sleep Network. Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea. Thorax 2016; 71 (10) 899-906
38 BaHammam AS, Aleissi SA, Nashwan SZ, Olaish AH, Almeneessier AS. Results of CPAP titration and short-term adherence rates in patients with obesity hypoventilation syndrome and mild/moderate obstructive sleep apnea. Nat Sci Sleep 2022; 14: 1137-1148
39 Priou P, Hamel JF, Person C. et al. Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome. Chest 2010; 138 (01) 84-90
40 Kessler R, Chaouat A, Schinkewitch P. et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest 2001; 120 (02) 369-376
41 Masa JF, Mokhlesi B, Benítez I. et al; Spanish Sleep Network. Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial. Lancet 2019; 393 (10182): 1721-1732
42 Piper AJ, Wang D, Yee BJ, Barnes DJ, Grunstein RR. Randomised trial of CPAP vs bilevel support in the treatment of obesity hypoventilation syndrome without severe nocturnal desaturation. Thorax 2008; 63 (05) 395-401
43 Salord N, Mayos M, Miralda RM. et al. Continuous positive airway pressure in clinically stable patients with mild-to-moderate obesity hypoventilation syndrome and obstructive sleep apnoea. Respirology 2013; 18 (07) 1135-1142
44 Lastra AC, Masa JF, Mokhlesi B. CPAP titration failure is not equivalent to long-term CPAP treatment failure in patients with obesity hypoventilation syndrome: a case series. J Clin Sleep Med 2020; 16 (11) 1975-1981
45 Castro-Añón O, Golpe R, Pérez-de-Llano LA. et al. Haemodynamic effects of non-invasive ventilation in patients with obesity-hypoventilation syndrome. Respirology 2012; 17 (08) 1269-1274
46 Masa JF, Mokhlesi B, Benítez I. et al; Spanish Sleep Network, Long-Term Pickwick Randomized Controlled Clinical Trial. Echocardiographic changes with positive airway pressure therapy in obesity hypoventilation syndrome. Am J Respir Crit Care Med 2020; 201 (05) 586-597
47 Castro-Añón O, Pérez de Llano LA, De la Fuente Sánchez S. et al. Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome. PLoS One 2015; 10 (02) e0117808
48 Howard ME, Piper AJ, Stevens B. et al. A randomised controlled trial of CPAP versus non-invasive ventilation for initial treatment of obesity hypoventilation syndrome. Thorax 2017; 72 (05) 437-444
49 de Llano LP, Castro-Añón O, Castro-Cabana L, Méndez Marote L, Golpe R. Long-term effectiveness of CPAP in patients with severe obesity-hypoventilation syndrome. Sleep Breath 2021; 25 (02) 947-950
50 Masa JF, Benítez ID, Sánchez-Quiroga MÁ. et al; Spanish Sleep Network, Authors from Spanish Sleep Network. Effectiveness of CPAP vs. noninvasive ventilation based on disease severity in obesity hypoventilation syndrome and concomitant severe obstructive sleep apnea. Arch Bronconeumol 2022; 58 (03) 228-236
51 Corral J, Mogollon MV, Sánchez-Quiroga MÁ. et al; Spanish Sleep Network. Echocardiographic changes with non-invasive ventilation and CPAP in obesity hypoventilation syndrome. Thorax 2018; 73 (04) 361-368
52 Masa JF, Mokhlesi B, Benítez I. et al; Spanish Sleep Network. Cost-effectiveness of positive airway pressure modalities in obesity hypoventilation syndrome with severe obstructive sleep apnoea. Thorax 2020; 75 (06) 459-467
53 Jennum P, Kjellberg J. Health, social and economical consequences of sleep-disordered breathing: a controlled national study. Thorax 2011; 66 (07) 560-566
54 Carrillo A, Ferrer M, Gonzalez-Diaz G. et al. Noninvasive ventilation in acute hypercapnic respiratory failure caused by obesity hypoventilation syndrome and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186 (12) 1279-1285
55 Romero C, Sánchez J, Almadana V. et al. Results of noninvasive ventilation in obese patients with acute respiratory . failure. [abstract] Chest 2014; 145 (3 Suppl): 544A